CVS Group stock rises after meeting profit expectations despite revenue miss

Published 24/07/2025, 10:00
 CVS Group stock rises after meeting profit expectations despite revenue miss

Investing.com -- CVS Group stock gained 4% after the veterinary services provider reported meeting profit expectations for fiscal year 2025 despite revenue coming in slightly below analyst forecasts.

The company reported revenue of £673 million for the year ended June 30, representing 5.4% growth year-over-year in continuing operations. However, this figure fell 1% short of Factset consensus estimates of £682 million. Like-for-like growth was modest at just 0.2% overall and 1.0% in its practice division, with the company citing softer UK market conditions as a factor.

Despite the revenue shortfall, CVS Group expects adjusted EBITDA to reach approximately £134 million, translating to a margin of around 20%, which aligns with analyst expectations. The company noted some improvement in market conditions during the final quarter of the fiscal year.

CVS Group has been actively expanding in Australia, completing 15 practice acquisitions during the fiscal year for a total consideration of approximately £29.2 million. Since entering the Australian market in July 2023, the company has acquired 30 practices across 45 sites. Meanwhile, its UK acquisition activity remains on hold pending the outcome of a Competition and Markets Authority (CMA) investigation, though the company expressed confidence in "accretive UK acquisition opportunities in due course."

The company’s balance sheet showed net bank borrowings of £131 million at year-end, benefiting from £42 million in proceeds from the disposal of its Crematoria business. Leverage is expected to be approximately 1.2x, down from 1.7x in December 2024 and within the company’s target of less than 2x.

While CVS Group did not provide specific guidance for fiscal year 2026, it stated it is "well placed to deliver further inorganic revenue and adjusted EBITDA growth." The company reaffirmed its mid-term margin guidance range of 19-23%.

Due to the CMA’s delay in its preliminary decision to September, CVS Group will report full fiscal year results on October 7.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.